source: treatment episode data set (teds) 2005source: treatment episode data set (teds) 2005...
TRANSCRIPT
![Page 1: SOURCE: Treatment Episode Data Set (TEDS) 2005SOURCE: Treatment Episode Data Set (TEDS) 2005 Admissions to Substance Abuse Treatment for the Abuse of Opioid](https://reader036.vdocuments.us/reader036/viewer/2022062722/56649f2b5503460f94c45e74/html5/thumbnails/1.jpg)
Admissions to Substance Abuse Treatment for the Admissions to Substance Abuse Treatment for the Abuse of Opioid Analgesics:Abuse of Opioid Analgesics:
Findings from theFindings from the Treatment Episode Data SetTreatment Episode Data Set
Deborah TrunzoOffice of Applied Studies
Substance Abuse and Mental Health Services Administration
November 13, 2008
![Page 2: SOURCE: Treatment Episode Data Set (TEDS) 2005SOURCE: Treatment Episode Data Set (TEDS) 2005 Admissions to Substance Abuse Treatment for the Abuse of Opioid](https://reader036.vdocuments.us/reader036/viewer/2022062722/56649f2b5503460f94c45e74/html5/thumbnails/2.jpg)
Treatment Episode Data Set (TEDS)
• Client-level information on treatment admissions
• Collected by States and reported to SAMHSA
• Primarily from facilities receiving public funds
• Estimated coverage – 80%
• 1.8 million admissions annually
2
![Page 3: SOURCE: Treatment Episode Data Set (TEDS) 2005SOURCE: Treatment Episode Data Set (TEDS) 2005 Admissions to Substance Abuse Treatment for the Abuse of Opioid](https://reader036.vdocuments.us/reader036/viewer/2022062722/56649f2b5503460f94c45e74/html5/thumbnails/3.jpg)
TEDS Data Elements
• Demographic variables
• Drug use history – top 3 substances of abuse at admission– route of administration– frequency of use– age at first use
• Treatment variables
3
![Page 4: SOURCE: Treatment Episode Data Set (TEDS) 2005SOURCE: Treatment Episode Data Set (TEDS) 2005 Admissions to Substance Abuse Treatment for the Abuse of Opioid](https://reader036.vdocuments.us/reader036/viewer/2022062722/56649f2b5503460f94c45e74/html5/thumbnails/4.jpg)
Limitations of TEDS
• Drugs of abuse reported in “generic” categories, not specific brand names or formulations
• All States report on “opiates other than heroin” as a group
• Only 16 States report on specific opioid analgesics
–
4
![Page 5: SOURCE: Treatment Episode Data Set (TEDS) 2005SOURCE: Treatment Episode Data Set (TEDS) 2005 Admissions to Substance Abuse Treatment for the Abuse of Opioid](https://reader036.vdocuments.us/reader036/viewer/2022062722/56649f2b5503460f94c45e74/html5/thumbnails/5.jpg)
Treatment Admissions by Primary Substance: 2006
Alcohol39%
Marijuana16%
Cocaine14%
Heroin14%
Stimulants9%
Opioid analgesics*
4%
Other4%
* Includes admissions where primary substance was reported as Other opiates/synthetics. Excludes admissions for non-prescription use of methadone.
N = 1.8 million
5
![Page 6: SOURCE: Treatment Episode Data Set (TEDS) 2005SOURCE: Treatment Episode Data Set (TEDS) 2005 Admissions to Substance Abuse Treatment for the Abuse of Opioid](https://reader036.vdocuments.us/reader036/viewer/2022062722/56649f2b5503460f94c45e74/html5/thumbnails/6.jpg)
Treatment Admissions Involving Opioid Analgesics1
1992-2006
0
20
40
60
80
100
120
140
1992 1994 1996 1998 2000 2002 2004 2006
No
. o
f ad
mis
sio
ns (
000s)
1 Includes admissions where primary, secondary, or tertiary substance was reported as Other opiates/synthetics. Excludes admissions for non-prescription use of methadone.
OxyContin introduced
6
![Page 7: SOURCE: Treatment Episode Data Set (TEDS) 2005SOURCE: Treatment Episode Data Set (TEDS) 2005 Admissions to Substance Abuse Treatment for the Abuse of Opioid](https://reader036.vdocuments.us/reader036/viewer/2022062722/56649f2b5503460f94c45e74/html5/thumbnails/7.jpg)
Percent Increase in Admissions for Heroin and Opioid Analgesics1: 1997-2006
12% 4%
367%
295%
0
50
100
150
200
250
300
350
400
Totaladmissions
Heroin (primary) Opioidanalgesics
(primary)
Opioidanalgesics
(any)
% i
ncre
ase
1 Includes admissions where primary, secondary, or tertiary substance was reported as Other opiates/synthetics. Excludes admissions for non-prescription use of methadone.
7
![Page 8: SOURCE: Treatment Episode Data Set (TEDS) 2005SOURCE: Treatment Episode Data Set (TEDS) 2005 Admissions to Substance Abuse Treatment for the Abuse of Opioid](https://reader036.vdocuments.us/reader036/viewer/2022062722/56649f2b5503460f94c45e74/html5/thumbnails/8.jpg)
Admissions Involving Specific Opioid Analgesics1: 2006
Oxycodone 15,300
Codeine 1,200
Hydrocodone 900
Hydromorphone 800
Propoxyphene 162
Meperidine 80
Pentazocine 30
Tramadol 50
Other opiates or synthetics 33,100
1Data submitted by 16 States: AL, HI, ID, KY, MD, ME, MO, MS, ND, NH, NJ, NM, NV, NY, OH, SD
8
![Page 9: SOURCE: Treatment Episode Data Set (TEDS) 2005SOURCE: Treatment Episode Data Set (TEDS) 2005 Admissions to Substance Abuse Treatment for the Abuse of Opioid](https://reader036.vdocuments.us/reader036/viewer/2022062722/56649f2b5503460f94c45e74/html5/thumbnails/9.jpg)
States Reporting Specific Opioid Analgesics: 2006
9
![Page 10: SOURCE: Treatment Episode Data Set (TEDS) 2005SOURCE: Treatment Episode Data Set (TEDS) 2005 Admissions to Substance Abuse Treatment for the Abuse of Opioid](https://reader036.vdocuments.us/reader036/viewer/2022062722/56649f2b5503460f94c45e74/html5/thumbnails/10.jpg)
Percent Increase in Admissions for Specific Opioid Analgesics1:2000-2006
137% 121%19%
1,513%
67%
-60%
168%
-200
0
200
400
600
800
1,000
1,200
1,400
1,600
All op
ioid
anal
gesic
s
Codeine
Hydro
morp
hone
Mep
erid
ine
Oxyco
done
Penta
zoci
ne
Propoxy
phene
% i
nc
rea
se
1 Includes admissions where primary, secondary, or tertiary substance was reported as Other opiates/synthetics. Excludes admissions for non-prescription use of methadone. Analysis restricted to 13 States that reported detailed drug codes for 2000 and 2006.
10
![Page 11: SOURCE: Treatment Episode Data Set (TEDS) 2005SOURCE: Treatment Episode Data Set (TEDS) 2005 Admissions to Substance Abuse Treatment for the Abuse of Opioid](https://reader036.vdocuments.us/reader036/viewer/2022062722/56649f2b5503460f94c45e74/html5/thumbnails/11.jpg)
1 Includes admissions where primary, secondary, or tertiary substance was reported as Other opiates/synthetics. Excludes admissions for non-prescription use of methadone.
Proportion of Opioid Analgesic1 Admissions by State: 2006
8-9%
< 5%
5% No data
6-7% > 16%
11
![Page 12: SOURCE: Treatment Episode Data Set (TEDS) 2005SOURCE: Treatment Episode Data Set (TEDS) 2005 Admissions to Substance Abuse Treatment for the Abuse of Opioid](https://reader036.vdocuments.us/reader036/viewer/2022062722/56649f2b5503460f94c45e74/html5/thumbnails/12.jpg)
Opioid Analgesic1 Treatment Admission Rates by Urbanization: 2000 and 2006
23
1623
30 28 26
55
31
58
68
7671
0
10
20
30
40
50
60
70
80
90
Total US LargeMSA, inCentral
City
LargeMSA, Notin Central
City
Small MSA Non-MSA,Small City
Non-MSA,No City
Pe
r 1
00
,00
0 a
ge
12
& o
ve
r
2000 2006
1 Includes admissions where primary, secondary, or tertiary substance was reported as Other opiates/synthetics. Excludes admissions for non-prescription use of methadone.
MSA = Metropolitan Statistical Area12
![Page 13: SOURCE: Treatment Episode Data Set (TEDS) 2005SOURCE: Treatment Episode Data Set (TEDS) 2005 Admissions to Substance Abuse Treatment for the Abuse of Opioid](https://reader036.vdocuments.us/reader036/viewer/2022062722/56649f2b5503460f94c45e74/html5/thumbnails/13.jpg)
Percent of Primary and Secondary Opioid Analgesic Admissions Using Other Substances: 2006
37
2220
17
107
59
29
13 15
3
29
6 5
0
0
40
NoneAlcohol
Marijuana
Cocaine
Tranquillizers
Heroin
Stimulants
Other/unknown
Perc
ent
Opiate Analgesics Primary Opiate Analgesics Secondary
13
![Page 14: SOURCE: Treatment Episode Data Set (TEDS) 2005SOURCE: Treatment Episode Data Set (TEDS) 2005 Admissions to Substance Abuse Treatment for the Abuse of Opioid](https://reader036.vdocuments.us/reader036/viewer/2022062722/56649f2b5503460f94c45e74/html5/thumbnails/14.jpg)
Treatment Admissions Involving Opioid Analgesics1 by Age and Route of Administration: 2006
0
1000
2000
3000
4000
10 15 20 25 30 35 40 45 50 55 60
No
. o
f a
dm
iss
ion
s
1 Includes admissions where primary, secondary, or tertiary substance was reported as Other opiates/synthetics. Excludes admissions for non-prescription use of methadone.
Age
Oral
Inhaled
InjectedOther
14
![Page 15: SOURCE: Treatment Episode Data Set (TEDS) 2005SOURCE: Treatment Episode Data Set (TEDS) 2005 Admissions to Substance Abuse Treatment for the Abuse of Opioid](https://reader036.vdocuments.us/reader036/viewer/2022062722/56649f2b5503460f94c45e74/html5/thumbnails/15.jpg)
Treatment Admissions Involving Oxycodone1 by Age and Route of Administration: 2006
0
50
100
150
200
250
300
350
400
450
10 15 20 25 30 35 40 45 50 55 60
No
. o
f ad
mis
sio
ns
1 Includes admissions where primary, secondary, or tertiary substance was reported as Oxycodone.
Age
Oral
Injected
Inhaled
Other
15
![Page 16: SOURCE: Treatment Episode Data Set (TEDS) 2005SOURCE: Treatment Episode Data Set (TEDS) 2005 Admissions to Substance Abuse Treatment for the Abuse of Opioid](https://reader036.vdocuments.us/reader036/viewer/2022062722/56649f2b5503460f94c45e74/html5/thumbnails/16.jpg)
Characteristics of Opioid Analgesic1 Admissions1997 and 2006
1997 2006
Male 56% 57%
White (non-Hispanic) 83% 88%
Less than 20 years of age
20 to 29 years
30 years or more
5%
16%
79%
11%
37%
52%
New users (3 yrs use or less) 20% 28%
Oral
Injected
Inhaled
78%
14%
3%
74%
10%
13%
1 Includes admissions where primary, secondary, or tertiary substance was reported as Other opiates/synthetics. Excludes admissions for non-prescription use of methadone.
16
![Page 17: SOURCE: Treatment Episode Data Set (TEDS) 2005SOURCE: Treatment Episode Data Set (TEDS) 2005 Admissions to Substance Abuse Treatment for the Abuse of Opioid](https://reader036.vdocuments.us/reader036/viewer/2022062722/56649f2b5503460f94c45e74/html5/thumbnails/17.jpg)
Admissions for Primary Opioid Analgesics1 by Age of First Use: 1997-2006
0%
25%
50%
75%
100%
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
% o
f adm
issi
ons
17 and under
18 - 24
25 - 34
35 - 44
55+
45 - 54
* Includes admissions where primary substance was reported as Other
opiates/synthetics. Excludes admissions for non-prescription use of methadone. 17